WC
KYTH

Wexford Capital’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Wexford Capital’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-20,000
Closed -$912K – 301
2013
Q3 		$912K Buy
+20,000
New +$598K 0.08% 119

Other funds holding KYTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wexford Capital's KYTH Position: Q4 2013 in Review

Wexford Capital sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q4 2013, closing a stake of 20,000 shares — an estimated $912K sold.

Wexford Capital first reported a position in KYTH in Q3 2013 and held it in 1 quarter. The position peaked at $912K in Q3 2013. 92 funds tracked by Wall St. Rank hold KYTH as of Q4 2013.

  • Wexford Capital reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q4 2013 after selling out during the quarter.
  • Wexford Capital sold 20,000 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q4 2013, an estimated $912K.
  • Wexford Capital first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q3 2013 and held it in 1 quarter.
  • Wexford Capital's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $912K in Q3 2013.
  • 92 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q4 2013.

Based on Wexford Capital's 13F filing for Q4 2013, filed 14 Feb 2014.